FDA Approved: VYXEOS — Supplemental Application (Jazz Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for VYXEOS (daunorubicin and cytarabine liposome) from Jazz Pharmaceuticals, Inc. This action reflects an update to …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with Myelodysplasia-related Changes
• Therapy-related Acute Myeloid Leukemia

Drugs mentioned

• Vyxeos (CPX-351)

Snippet

SUPPL AP for VYXEOS ((DAUNORUBICIN AND CYTARABINE) LIPOSOME)